Inspire Medical Systems, Inc. INSP
70.50
1.69
2.46%
as of 25 Sep
- Market cap
- $2.0B
- P/E
- 15.1×
Follow INSP
Growth Flags
show if company had growth for consecutive years
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
49.47 | 18.37 | 11.39 | 9.57 |
P/S ratio |
2.47 | 2.97 | 1.62 | 1.43 | |
P/FCF ratio |
22.02 | 34.52 | 15.31 | 10.99 | |
P/Operating CF |
31.76 | 51.62 | 115.21 | 55.38 | |
P/B ratio |
3.27 | 3.47 | 1.87 | 1.56 | |
Price to Tangible BV |
3.27 | 3.47 | 1.87 | 1.56 | |
EV/Sales |
2.13 | 2.66 | 1.33 | 1.10 | |
EV/EBITDA |
41.49 | 39.11 | 18.69 | 14.15 | |
EV/Operating CF |
14.06 | 20.74 | 8.95 | 6.31 | |
EV/FCF |
19.01 | 30.91 | 12.63 | 8.46 | |
Quick Ratio |
3.88 | 4.46 | 4.35 | 5.96 | |
Current Ratio |
5.29 | 6.08 | 6.34 | 8.55 | |
Net Debt/EBITDA |
(24.95) | (6.22) | (76.67) | (83.38) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
1.10 | 1.06 | 1.11 | 1.04 | |
Operating CF/Net income |
6.90 | 0.39 | (1.14) | 73.97 | |
Capex/Depreciation |
(3.18) | (3.09) | (2.02) | (2.10) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
10.78% | 9.27% | 12.62% | 12.31% | |
Selling, General and Administrative Expense of Revenue |
70.77% | 60.19% | 74.40% | 73.42% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
13.13% | 10.41% | 15.00% | 15.57% | |
Graham Net Nets |
0.20 | 0.17 | 0.30 | 0.40 | |
Graham Number |
27.69 | 54.81 | 53.05 | 54.79 | |
Earnings Yield |
2.02% | 5.44% | 8.78% | 10.45% | |
Free Cash Flow Yield |
4.54% | 2.90% | 6.53% | 9.10% | |
Revenue per Share |
7.65 | 9.16 | 7.13 | 6.96 | |
Operating CF per Share |
2.34 | 1.79 | 0.45 | 0.81 | |
Capex per Share |
(0.36) | (0.36) | (0.34) | (0.32) | |
Free Cash Flow per Share |
1.98 | 1.42 | 0.11 | 0.49 | |
Cash per Share |
11.00 | 10.50 | 9.89 | 11.12 | |
Shareholders Equity per Share |
22.72 | 26.60 | 27.61 | 28.63 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
22.72 | 26.60 | 27.61 | 28.63 | |
Free Cash Flow |
58.09 | 41.81 | 3.12 | 14.07 | |
Working Capital |
475.65 | 487.60 | 477.40 | 537.49 | |
Capital Expenditures |
(10.44) | (10.66) | (9.73) | (9.16) | |
Net Current Asset Value |
445.23 | 457.50 | 447.78 | 508.26 | |
EV/EBIT |
51.16 | 47.60 | 23.81 | 18.31 | |
Capex to Sales |
0.05 | 0.04 | 0.05 | 0.05 | |
Net Profit Margin |
4.42% | 50.58% | (5.52%) | 0.16% | |
Price to Operating Income |
59.26 | 53.16 | 28.85 | 23.77 | |
| Other line items | |||||
Average Receivables |
98.87 | 106.38 | 98.86 | 120.51 | |
Average Payables |
47.08 | 37.63 | 35.49 | 40.13 | |
Average Inventory |
104.60 | 112.71 | 132.98 | 146.04 | |
Average Assets |
801.96 | 857.85 | 821.09 | 864.09 | |
Average Common Equity |
681.51 | 735.43 | 714.04 | 751.70 |
Columns are period end dates